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Highlights 
 In treatment seeking patients with generalised anxiety disorders, cranioelectrostimulation is 
as effective against anxiety and depression symptoms, confirming previous meta-analysis of 
randomised controlled trials of volunteers with anxiety; 
 Rates of remission of anxiety at 12 and 24 weeks are slightly lower than individual cognitive 
behaviour therapy; 
 The clinical effects of 6-12 weeks daily CES are maintained for a further 12 weeks without 
using CES; 
 Compared to individual cognitive behaviour therapy, alpha-stim CES is cheaper to use 
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Abstract 
Background. Cranial electrotherapy stimulation (CES) is a well-tolerated neuromodulation treatment 
with demonstrated trial efficacy in anxiety disorders. The aim of the current study was to 
demonstrate its clinical and cost effectiveness during and after CES in people with generalised 
anxiety disorder (GAD) who had not responded to low intensity psychological treatment in a routine 
health service. 
Methods. Consecutive sample of eligible patients with GAD waiting for individual cognitive 
behaviour therapy (CBT) selected from two publicly funded services in England. They received 60 
minutes per day Alpha-Stim CES for 6-12 weeks. Primary outcome was remission on the GAD-7 scale 
at 12 and 24 weeks. Cost effectiveness was examined using a cost minimisation model of direct 
health costs.  
Results. Of 161 patients recruited, 72 (44.7%) and 77 (47.8%) achieved remission on the GAD-7 at 12 
and 24 weeks respectively with 122 (75.8%) receiving at least 6 weeks CES. Mean (sd) GAD-7 score at 
baseline significantly improved from 15.77 (3.21) to 8.92 (5.42) and 8.99 (6.18) at 12 and 24 weeks 
respectively (p<0.001).  80 (49.7%) participants required further individual CBT. CES provided a 
saving of £540.88 per patient (95% CI -£327.12, £648.69). 
Limitations. Participants were not randomised and there was no control group.  Only 48 (29.9%) 
participants completed every assessment.  
Conclusion. In patients with generalised anxiety disorder not responding to low intensity 
psychological treatment, 6-12 weeks daily Alpha Stim CES may be effective after treatment and 3 
months later, thereby reducing the need for individual CBT and saving health costs.  
247 words 
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Abbreviations 
AIS - Athens Insomnia Scale; Alpha-Stim AID - cranial electrotherapy stimulator for control of anxiety, 
insomnia and depression; CBT - cognitive behaviour therapy; CE - Conformité Européene, European 
Union regulatory marking; CES - cranial electrotherapy stimulation; CI - confidence interval; CSRI - 
Client Service Receipt Questionnaire; DSM-IV- Diagnostic and Statistical Manual of Mental Disorders 
4th Edition; EEG - electroencephalography; EQ5D-5L - Euroqol; FIML - full information maximum 
likelihood estimation; fMRI – functional magnetic resonance imaging; GAD - generalised anxiety 
disorder; GAD-7 – self-rated measure of generalised anxiety disorder symptoms; GLM - general 
linear model; HE – health economics; iCBT – individual cognitive behaviour therapy; IAPT - Improving 
Access to Psychological Treatment service; IRAS – Integrated Research Application Service; ITT - 
intention to treat; MCAR - missing completely at random; NHS - National Health Service; NICE - 
National Institute for Clinical Excellence; NRES – National Research Ethics Service; PHQ-9 - Personal 
Health Questionnaire 9 item; PSA - Probabilistic sensitivity analysis; PSSRU - Personal Social Services 
Research Unit; RCT - randomised controlled trial; RM ANOVA - repeat measures analysis of variance; 
WASA - Work and Social Adjustment Scale 
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Introduction 
Generalised anxiety disorder (GAD) is a common and persistent mental disorder with a point or 
annual prevalence of 2.1 to 4.4% (Hunt et al, 2002; Grant et al, 2005; Remes et al, 2017; Ruscio et al, 
2017). GAD is often present with other mental disorders such as depression, other anxiety disorders, 
insomnia and physical illness (Chapman et al 2010; Ruscio et al, 2017), all of which can lead to 
considerable health expenditure (Sandelin et al, 2013).  According to the National Institute for 
Clinical Excellence (NICE) Guideline for Generalised Anxiety Disorder for England and Wales (NICE, 
2011), the first step in the management of GAD is education about the condition and monitoring 
delivered in primary care. The second step is low intensity psychological intervention of the person’s 
choice, which is provided by the Improving Access to Psychological Treatment service (IAPT) in all 
parts of the National Health Service in England (NICE, 2011), usually in the form of facilitated 
computerised cognitive behaviour therapy or bibliotherapy (Gyani et al, 2013). While these 
approaches are relatively cheap and effective, many people with GAD do not improve and require 
additional treatment (Andrews et al, 2018). The third step NICE recommended intervention is either 
a high intensity psychological intervention such as individual cognitive behaviour therapy (iCBT), also 
delivered by IAPT services and relatively expensive, or drug treatment, initially with selective 
serotonin reuptake inhibitor antidepressants but if these are ineffective then more expensive drugs 
such as pregabalin are used. There can be a substantial delay before iCBT can be offered (Sandelin et 
al, 2013). 
 
Cranial electrotherapy stimulation (CES) was first utilised to induce sleep and relaxation using bursts 
of small electric currents applied to the head in the 1900s (Guleyupoglu et al, 2013). Improvements 
have taken place in electrode placement, use of battery driven devices and understanding of dose, 
frequency of treatment and waveform that is required to improve anxiety symptoms. Single courses 
of CES are associated with changes in electroencephalography (EEG) from delta (0-3.5Hz) and beta 
(12.5-30Hz) frequencies to more relaxing and alerting alpha frequencies (8-12 Hz) (Kennerly, 2004). 
Cortical and subcortical brain activation on fMRI have been demonstrated  in people with high levels 
of anxiety (Feusner et al, 2012) and increases in plasma beta endorphins, adrenocorticotrophic 
hormone and cortisol (Liss and Liss, 1996; Shealy et al, 1998) after a single 20 minute CES treatment.   
 
A recently published systematic review funded by the United States Department of Veteran Affairs 
identified five randomised controlled trials (RCTs) with 198 participants for anxiety disorders 
comparing active CES to sham CES (Shekelle et al, 2018). It concluded that there was low quality 
evidence of the effectiveness of CES for anxiety and depression symptoms in people with anxiety 
disorders at the end of treatment as well as evidence that CES does not cause serious side effects. A 
randomised controlled trial in 115 volunteers with a primary anxiety disorder showed the 
effectiveness of 5 weeks of active CES versus sham CES on anxiety and depression symptoms at the 
end of treatment (Barclay and Barclay, 2014). However, there have been no studies of the 
maintenance of clinical improvement or cost effectiveness of CES in treatment seeking patients with 
GAD who had not responded to second-line treatment as recommended by NICE (2011). Therefore 
we examined the clinical and cost effectiveness of 6-12 weeks CES treatment for treatment seeking 
patients with GAD who had not responded to facilitated computerised cognitive behaviour therapy 
or bibliotherapy over 24 weeks. These patients were all waiting for iCBT for GAD. 
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There are four aims to the current study to determine: 
1. The proportion of patients treated with CES in IAPT services who reach the clinical threshold 
for remission (GAD-7 score of 7 or less; Spitzer et al, 2016), reliable improvement and 
recovery after treatment at 12 weeks. 
2. The proportion of patients treated with CES in IAPT services who maintain the clinical 
threshold for remission (GAD-7 score of 7 or less), reliable improvement and recovery at 24 
weeks. 
3. If there are significant changes over 24 weeks in generalised anxiety, depression, insomnia, 
social adjustment and quality of life. 
4. If the cost of CES offsets the cost of psychological treatment and other treatment over 24 
weeks. 
 
Method 
Design. This is a study in routine care carried out after efficacy has been established against sham 
treatment in a meta-analysis of RCTs (Shekelle et al, 2018) to establish the effectiveness and costs in 
routine care settings as outlined by the United Kingdom Medical Research Council Complex 
Intervention Framework (2000) and the National Institute for Health and Care Excellence (2018). An 
open consecutive patient cohort design with 24 week follow up in National Health Service (NHS) 
mental health treatment settings in England was employed where all participants were offered 
Alpha-Stim cranial electrotherapy stimulation (CES) for 6-12 weeks if they had not reached remission 
with therapist or full guided self-help and were waiting to receive individual cognitive behaviour 
therapy (iCBT).  
Setting. Two NHS Improving Access to Psychological Treatment (IAPT) services in the same county in 
England covering a more affluent urban and rural area and a less affluent inner city area. The 
services were run by two different NHS organisations. All data and treatment were delivered by staff 
who were independent of the company who makes Alpha Stim CES.  Ethical approval for the study 
was granted by the Nottingham 2 NRES committee (IRAS206555). 
Inclusion/exclusion criteria: 
1. A score of 8 or more on GAD-7 scale, a 7-item self-rated measure of symptoms of 
generalised anxiety disorder (Spitzer et al, 2016), because nationally IAPT services determined that 
further treatment should be offered after full or guided computerised self-management or 
bibliotherapy if a person scores above the threshold for remission i.e. a total score of 8 or more. 
2. A clinical diagnosis of generalised anxiety disorder alone or in combination with a comorbid 
depression or other anxiety disorder e.g. obsessive compulsive disorder or physical health morbidity. 
Excluded was a diagnosis of any other mental disorder e.g. substance use disorder, eating disorder, 
bipolar disorder, non-affective psychosis. In keeping with an implementation study the diagnostic 
information used for the inclusion and exclusion criteria were made on clinical grounds without 
using any standardised psychiatric interviews by clinically qualified mental health professionals 
independently of the research team.  
3. On waiting list for individual CBT (high intensity psychological intervention). 
4. Does not require urgent clinical care.  
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5. If female not known to be pregnant. 
6. Implantation with a pace maker or an implantable cardioverter device (ICD) are exclusions. 
6. Gives informed written and oral consent to the study. 
7. Agrees to return Alpha-Stim equipment at the end of the study. 
Being on medication did not lead to exclusion. 
Outcome measures: 
These are standard clinical outcome measure employed routinely by the NHS IAPT services with the 
addition of measures of insomnia, quality of life and an economic interview to assess health costs. 
They were collected face to face at baseline. Clinical outcome and quality of life measure were 
collected at four, six, eight, 12 and 24 weeks by e-mail, telephone or post according to participant 
preference.  A second economic interview was conducted by telephone or Skype at six months 
according to participant preference. All participants who completed the economic interview were 
given a £10 gift voucher in recognition of the time given to completing the research outcome 
assessments.  
 
Primary outcome measure:  
The primary outcome is the proportion of participants who reach remission (7 points or less) at 12 
and 24 weeks on the GAD-7 since IAPT services are paid according to the proportion of patients who 
reach this threshold after treatment in their service (Richards and Borglin, 2011). Other key 
outcomes are the proportion of cases who meet a clinically important (“reliable improvement”) 5  
point improvement on the GAD-7 at 12 and 24 weeks (Richards and Borglin, 2011), the proportion 
who meet criteria for recovery (GAD-7 score of 7 or less and also exhibiting a 5 point drop in GAD-7 
score) at 12 and 24 weeks (Richards and Borglin, 2011), and the effect size of the change in GAD-7 
score over 12-24 weeks. A clinically important deterioration is an increase in GAD-7 score of 5 points 
at 12 and 24 weeks (Richards and Borglin, 2011).    
Secondary outcome measures:  
1. Personal Health Questionnaire, 9-item (PHQ-9; Kroenke et al, 2001), a 9-item self-rated 
measure of the severity of depression symptoms. Remission is a total score of 9 or less at 12 or 24 
weeks in those who had scored 10 or more at baseline, reliable improvement is a drop of 6 points or 
more, and recovery is a score of 9 or less and a 6 point drop at 12 and 24 weeks (Richards and 
Borglin, 2011). We also examined the effect size of the change in PHQ-9 score symptoms from 
baseline to 12 and 24 weeks. 
2. Athens Insomnia Scale (AIS; Soldatos et al, 2000).  This scale has 8 items with a maximum 
score of 24. A score of 6 indicates a possible sleep problem and 4 indicates recovery (Soldatos et al, 
2003). Therefore remission is defined as the proportion of people who score a total of 4 or less at 12 
and 24 weeks. No data exists on reliable improvement so a drop of 50% in baseline score by 12 and 
24 weeks was used. Recovery is the proportion of people who showed a drop of 50% in baseline 
score and scored 4 or less at 12 and 24 weeks. We also examined the effect size of the change in 
insomnia symptoms from baseline to 12 and 24 weeks. 
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3. Work and Social Adjustment Scale (WASA; Mundt et al, 2002), an 8-item self-rated measure 
of work and social function. A total score of 20 or more indicates considerable impairment in 
function (Mundt et al, 2002). A return to normal function requires a total score of 10 or less and 
functional recovery requires a total score of 11 or more at baseline with a drop to 10 points or below 
by 12 and 24 weeks (Mundt et al, 2002). We also examined the effect size of the change in WASA 
score from baseline to 12 and 24 weeks. 
4. EQ5D-5L (EuroQol, van Hout et al, 2012), a 6- item self-rated measure of health utility and 
quality of life. We examined the effect size of the change in EQ5D-5L from baseline to 12 and 24 
weeks. 
 
Economic interview: 
We used the Client Service Receipt Interview (CSRI; Beecham and Knapp, 1992) adapted for use in 
studies of anxiety disorders in primary care and community settings. It was completed at baseline 
and 24 weeks. 
 
Procedure. 
Consecutive treatment seeking patients who received low intensity IAPT interventions (therapist 
guided self-management on a computerised CBT programme or bibliotherapy for GAD) but had not 
reached a total score of 8 or more, were unlikely to meet any exclusion criteria for the study, and 
were willing to be placed on a waiting list for iCBT, were identified from IAPT service records.  IAPT 
staff contacted a potential participant to seek permission for their contact details to be passed to 
the study team who checked their eligibility over the phone. A face to face meeting was arranged 
with a member of the study team who checked the inclusion/exclusion criteria and sought written 
informed consent. If the participant consented study staff showed the participants how to use the 
Alpha-Stim CES device, outlined how to obtain support while using it, and negotiated the return of 
the CES device at the end of 6-12 weeks treatment.  Women of child-bearing potential completed a 
urine pregnancy dipstick human chorionic gonadotropin test.   
Alpha-Stim AID is a CE marked medical device which is marketed for the alleviation of psychological 
conditions including anxiety, insomnia and depression, through using cranial electrotherapy 
stimulations (CES) which are tiny electric currents applied through ear clips worn for 60 minutes per 
day. The treatment provided by the device is therefore non-invasive, non-pharmacological, and can 
be used as adjunctive treatment to drug or psychological treatment or a treatment on its own. All 
participants were offered 60 minutes per day of alpha-stim CES treatment at a current of one 
hundred micro amps per day 7 days per week for 6 consecutive weeks. The 60 minutes session starts 
when the ear clips are attached and stops automatically when the hour is finished. The device was 
not locked because it would not be in usual clinical practice. The device did not automatically record 
adherence to treatment.  Participants could choose to continue with the same CES treatment for a 
further 6 weeks, thereby completing 12 weeks CES treatment in total.   At the end of 12 weeks the 
participants could not receive any further CES treatment. Since this was a naturalistic study, 
decisions concerning if and when iCBT might be received by the participant were made by IAPT staff 
with the participants; the study team did not influence this decision. If participants started iCBT 
during the 6-12 weeks of CES, they could continue with CES while receiving iCBT at the same time. 
Similarly general practitioners could independently decide to place the patient on medication for 
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GAD at the same time as participants continued to receive CES. A summary of the procedures of the 
study is shown in Table 1; as well as outcome measures, adherence to CES and side-effects were 
recorded at each study visit. 
Sample size.  
A meta-analysis of 5 CES RCTs estimates an effect size of at least 0.60 (Shekelle et al, 2018). On this 
basis remission might be expected in 26.5% patients with GAD receiving alpha stim CES in IAPT 
settings. The aim was to recruit a sample with at least 25 participants achieving remission after alpha 
stim CES at 12 weeks and followed up at 24 weeks; a sample of 160 would be required assuming 
40% loss to follow up by 24 weeks.  
Statistical analyses. 
Prior to statistical analyses, data screening was conducted to evaluate the tenability of assumptions 
specific to the general linear model (GLM). These assumptions included normally distributed 
outcome variables, independence of observations for different subjects, and homogeneity of 
covariance matrices within subjects across repeated measurements. The assumptions of the GLM 
were tenable except for homogeneity of covariance within subjects on their measurements over 
time. The Greenhouse-Geiser adjustment was applied to F-statistics and degrees of freedom when 
violations appeared. After data screening, analyses proceeded using a within-subjects repeated 
measures analysis of variance (RM ANOVA) for the primary outcome and secondary outcome 
variables. Additionally, regarding aims 1 and 2, descriptive analyses were conducted to determine 
remission, reliably improvement and recovery.   
To answer our research aim 3, we used a within-subjects univariate repeated measures analysis of 
variance (RM ANOVA). Separate univariate RM ANOVAs were conducted for each outcome variable 
in two distinct phases. The first set of analyses proceeded using data from the empirical sample. The 
second set of RM ANOVA analyses included an intention-to-treat (ITT) analysis strategy using a full 
complement of scores on each outcome variable. The following section includes information specific 
to the ITT analytic approach.  
Intention-to-treat (ITT) analysis avoids overoptimistic estimates of the efficiency of an intervention 
resulting from the removal of non-compliers by accepting that noncompliance and protocol 
deviations are likely to occur in clinical practice.  Intention-to-treat analyses was applied including all 
patients as they were assigned at baseline, regardless of their adherence to treatment, the 
treatment they received or any subsequent withdrawal from the study (Fisher, 1990).  To evaluate 
the type or pattern of missing scores for each outcome measure, the missing completely at random 
(MCAR) test was employed (Little and Rubin, 2002; Enders, 2010). Once the data was determined to 
adhere to MCAR (i.e. p >.05), replacement of scores proceeded using model-based full information 
maximum likelihood (.FIML) estimation. 
 
Health economics 
In order to determine the cost impact of introducing CES into the pathway as a second-line 
treatment instead of or prior to individual CBT (iCBT), a cost minimisation analysis was undertaken 
using a health economic (HE) model decision tree (see Figure 1). In both branches of the HE model 
the patient population was non-responders to low-intensity guided or full computerised self-help or 
bibliotherapy given as the first-line treatment. The decision tree was populated with the 
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probabilities of response to second line CES treatment from the study versus second-line iCBT with 
the remission rate of 54.2% from Gyani et al (2013) which is the average remission rate between 
guided and full self-help groups in that study. In addition, the same probability of outcome from 
subsequent iCBT sessions given to non-responders in both arms was modelled as in the current 
pathway (treatment as usual) such that for non-responders to second-line iCBT a further course of 
the same number of iCBT sessions would follow. For non-responders to second-line CES up to two 
further courses of iCBT were included in the decision tree. In all cases successful response was 
measured by the achievement of the GAD-7 threshold of remission as used in the IAPT programme 
(Richards and Borglin, 2011). Neither a cost-utility analysis nor a cost-consequences analysis was 
employed because the study did not have a comparator for outcomes although EQ-5D results are 
reported here separately for Alpha-stim CES treatment. 
The hypothesis tested in the HE model was that adding CES as a second-line treatment in the 
pathway will eliminate, for the proportion of patients who respond to CES, the need for the more 
expensive iCBT leading to cost savings. Although not included in the model, it would also potentially 
reduce waiting times for those patients who would still progress to iCBT since early response to 
available CES therapy promises to free up therapist resource for iCBT as well as potentially the 
number of iCBT sessions each participant would need after receiving CES.  The HE model used a 6-
month time horizon, reflecting the expected duration of GAD response (NICE, 2011) and including 
the time period for consecutive treatments of CES and/or iCBT.  Given this short time horizon, costs 
were not discounted.  
The modelling was undertaken from the United Kingdom NHS payer perspective with prices uplifted 
using the most recent national annually published resource, the PSSRU Unit Costs of Health and 
Social Care 2017 (Curtis and Burns, 2017) which gave compounded ratios for an uplift up to 2016. 
Costs were derived for CBT from Radhakrishnan et al (2013) for 60 or 90 minutes of iCBT (£98.59 or £ 
176.97 per session) uplifted from 2010 to 2016 prices using the appropriate ratio of 1.09 yielding £ 
£110.96 and £199.17 respectively. Overall treatment costs were computed for 8 sessions of 60 
minutes iCBT, as in the ‘standard of care’ model, yielding a total cost of £887.68. For comparison, the 
model was also constructed with alternative choices of two additional more expensive iCBT regimes: 
the ‘Clark and Wells model’ with 14 sessions of 90 minutes sessions of iCBT, costing £2788.43 in total 
and the ‘Heimberg model’ with one session of 90 minute iCBT followed by 15 sessions of 60 minutes 
iCBT, costing £1863.57 in total (NICE, 2013). 
Alpha-stim CES cost per treatment was a manufacturer estimate from the unit cost of the device of 
£450.00 (excluding valued added tax) with a utilisation of 15 patients over an average product 
lifetime of 3 years (based on a 10 week sole use per patient). It allowed for losses with respect to the 
quoted 5 year warranty that was estimated to reduce average product lifetime by 2 years. A 
Additional therapist time, postage and consumables was estimated at £40, yielding £70 per 
treatment. 
A probabilistic sensitivity analysis (PSA) was undertaken on cost of treatment, probability of 
response and utilisation of response with parameters as shown in Table 2 (York Health Economics 
Consortium, 2016). In addition a one-way deterministic threshold analysis was performed on cost to 
find the price at which the intervention would no longer be cost saving.  Probabilistic sensitivity 
analysis (PSA) is a technique used in economic modelling that allows the quantification of the level of 
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confidence in the output parameters of the analysis, in relation to the uncertainty in the model 
inputs. In the probabilistic analysis, the parameters’ value from clinical trials, observational studies 
or in some cases expert opinion are represented as distributions around their deterministic value. A 
set of input parameter values is drawn by random sampling from each distribution, and the model 
generates outputs (cost and health outcome), which are stored. This is repeated in many iterations 
of the model (typically 1,000 to 10,000), resulting in a distribution of outputs that can be graphed on 
the cost-effectiveness plane, and analysed. 
 
Results 
Figure 2 shows the flow of participants through the study. Only 22% of potentially eligible patients 
agreed to take in the study. All 161 participants started CES treatment and 112 (69.6%) completed at 
least 6 weeks treatment. Of the 49 (30.4%) participants who withdrew from treatment by 12 weeks, 
nine (5.6%) could not find the time to complete the treatment, four (2.5%) withdrew because of no 
improvement, four (2.5%) withdrew because of side effects (two with headaches and insomnia, one 
with nausea and one with a strange feeling after use), two (1.2%) withdrew because they felt better, 
and 30 (18.6%) gave no reason. Of the 161 participants, 80 (49.7%) had iCBT. Eighty-one (50.3%) 
completed follow ups to 12 weeks and 72 (44.7%) to 24 weeks. 
Table 2 shows that participants were drawn from a broad range of ages and nearly three quarters 
were female. The overwhelming majority were white British, most had at least high school 
education, married and were in employment. However, the mean baseline scores were in the severe 
range for GAD (Spitzer et al, 2001), moderately severe range for depression (Kroenke et al, 1999), 
showed significant sleep difficulties (Soldatos et al, 2004), substantial functional impairment (Mundt 
et al, 2002), and low health utility comparable to scores for out-patients with a broad range of 
physical and mental disorders (van Hout et al, 2012).  
Table 3 shows the primary outcome. By 12 weeks, 72 (44.7%) participants achieved remission and 
recovery on the GAD-7 at 12 weeks and 76 (47.2%) at 24 weeks. The proportions of participants 
achieving reliable improvement on the GAD-7 were 102 (63.4%) and 105 (65.2%) at 12 and 24 weeks 
respectively. No patient showed reliable deterioration at 12 or 24 weeks.  There was a drop in GAD-7 
score from mean (sd) 15.77 (3.21) to 8.92 (5.42) by 12 weeks and this is maintained to 8.99 (6.18) at 
24 weeks, a mild degree of GAD-7 symptoms by 12 and 24 weeks. The within-subjects effects is 
statistically significant (F=72.02, df1=3.7/df2=563.74, p<0.001) and the effect size is medium (partial 
eta square=0.31). The vast majority of the drop in GAD-7 is experienced in the first 6 weeks and 
there is no statistically significant difference between week 6 and any subsequent time point up to 
week 24. The same pattern is seen in 48 participants with assessments at every time point except 
the effect size of the within subjects treatment effect was large rather than medium (Appendix Table 
1).  Of the 81 participants who only received CES, 49 (60.3%) achieved remission on the GAD-7 at 12 
weeks and 53 (65.4%) achieved remission on the GAD-7 at 24 weeks. Of the 25 participants who 
received both CES and iCBT, 17 (68%) achieved remission and recovery on the GAD-7 and 23 (92%) 
achieved reliable improvement at 12 and 24 weeks.  
Table 3 shows that the effects on the PHQ-9 were similar in relation to the GAD-7 although a lower 
proportion achieved a reliable improvement at 12 and 24 weeks. The within subjects effect was 
significant (F=42.89, df1=3.9/df=559.01, p<0.001) with the mean PHQ-9 score dropping from the 
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moderately severe range to the mild range but the effect size was small (partial Eta square=0.21). 
There was some worsening of depression symptoms by week 24 and the fall in PHQ-9 score was only 
significant between baseline and 12 weeks but not 24 weeks. Only around a quarter of participants 
achieved remission on the Athens Insomnia Scale at 12 and 24 weeks. There was a statistically 
significant within-subjects drop in insomnia over the 24 period (F=42.69, df1=5.0/df=542.9, p<0.001) 
and the effect size was medium (partial Eta square=0.21).  
Table 3 also demonstrates that just over a quarter of participants made a functional recovery on the 
WASA at 12 and 24 weeks with CES. Figure 2 and Table 3 show that there is a significant within-
subjects effect of Alpha-Stim CES over the 24 weeks (F=17.35, df1=3.5/df=557.45, p<0.001) but the 
effect size is small (partial Eta square=0.10). The effects of Alpha-Stim CES on the EQ-5D-5L were 
very similar to the WASA with a significant within subjects effect over 24 weeks (F=13.94, 
df1=4.1/df2=651.3, p<0.0001) but the effect size is also small (partial Eta square=0.08).  
The results of the health economics decision tree model populated with the costs and probabilities 
for the 8 session standard care model of CBT yielded the results as shown in Table 4. The costs and 
responses are presented for a cohort of 1000 patients. CES provided a saving of -£540,878 (95% CI [-
£648,692, -£327,117]) and the number of responses to treatment were increased by 187.56 per 
1000 (95% CI [141.03, 227.82]). Using the “Clark and Wells model” of iCBT as comparator, CES 
provided a saving of -£1,637,410 (95% CIs -£1,914,463, -£1,175,437]) and the number of responses 
to treatment were increased by 187.56 per 1000 (95% CIs [141.58, 226.12]). With the Heimberg 
Model as a comparator, CES provided a saving of -£1,212,463 (95% CIs -£1,429,369, -£843,394]) and 
the number of responses to treatment were increased by 187.56 per 1000 (95% CIs [140.79., 
227.71]). Cost-outcome scatterplots for each model are shown in the Appendix.  
 
 
Discussion 
This study shows that in moderate to severe treatment seeking patients with GAD, nearly 45 per 
cent of patients achieved remission and 63 per cent reliable improvement in their self-rated anxiety 
symptoms with Alpha-Stim CES treatment.  These improvements were maintained for a further 12 
weeks after CES was completed whether or not patients received iCBT in addition. Most of the 
improvement with CES was seen in the first 4 weeks.  It had a moderate effect size. Remission rates 
are lower than  reported for iCBT in routine IAPT services in the UK (Radhakrishnan et al, 2013); 
however our sample had substantially higher scores than routinely reported for IAPT services 
(Radhakrishnan et al, 2013; NHS Digital, 2018). . Approximately 50 per cent of patients on the 
waiting list for iCBT received iCBT, thereby enabling the NHS IAPT services to treat other patients on 
the waiting list for iCBT. The mean severity of GAD-7 symptoms decreased from severe to mild and 
below case threshold over 12 weeks and remained at that level for 24 weeks. There were similar 
drops in depression symptoms and insomnia symptoms as well as improvements in function and 
quality of life although all of these effects were smaller with some slippage between 12 and 24 
weeks. Although there was a significant drop in depression symptoms between baseline and 12 
weeks, it was not significant at 24 weeks indicating that the effects of CES on depression symptoms 
had started to wane by 24 weeks. Overall a quarter of patients receiving CES regained a functional 
recovery. Alpha-Stim CES was well tolerated with only six (4%) patients stopping it because of side-
effects and four (3%) because they were not making any progress. Compared to a standard course of 
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iCBT (eight sessions or longer), Alpha-stim CES reduced costs of care by £540 or more per patient 
and it was also cost effective. 
The strengths of the study were that clinical and cost effectiveness was examined in a consecutive 
large sample of treatment seeking patients in universally available publicly funded services provided 
by the state irrespective of the ability to pay or health insurance. Inclusion criteria were set to reflect 
the criteria used by IAPT services to offer individual CBT. This criteria was set at 8 or more on the 
GAD-7 reflecting the upper end of mild severity compared to the usual clinical thresholds for mild , 
moderate and severe anxiety of 5, 10 and 15 on the GAD-7 (Spitzer et al, 2006). However 95 per cent 
of the sample had moderate or severe symptoms of GAD at baseline, well above the minimum 
threshold for entry to the study and the national NHS IAPT criteria for remission. They had already 
failed to improve with facilitated bibliography or computerised psychological treatment for GAD, so 
spontaneous improvement was unlikely. Placebo responses are less  frequent in research 
participants with less severe anxiety or depression and in those who have not responded to previous 
active treatment for their condition (Stein et al, 2006; Weimer et al, 2015). Therefore the study 
shows the effectiveness of CES in a clinical treatment seeking sample of patients with moderate to 
severe treatment resistant generalised anxiety disorder.  
There are important limitations of the study. There was no control group and the study was not a 
randomised controlled trial. However meta-analysis of previous RCTs of active CES versus sham CES 
already provides evidence that CES is effective in treating anxiety and depression symptoms 
(Shekelle et al, 2018).  The United Kingdom Medical Research Council (2000) and National Institute 
for Health and Care Excellence (2018) recommend that implementation studies are completed in 
routine treatment settings to check that the efficacy seen in RCTs is translated into routine clinical 
practice settings. This study was therefore designed to meet this requirement, to examine if 
effectiveness is maintained after CES treatment completion, and if there were any cost savings from 
CES treatment. Such studies do not necessarily utilise control groups; they must enrol treatment 
seeking patients studied under routine care delivery. Alpha-Stim CES was more effective at achieving 
remission than we expected from the effect size in a meta-analysis of RCTs (Shekelle et al, 2018) 
with 44.7% patients achieving remission, comparable to iCBT in routine treatment settings, rather 
than 26.5% patients as we had planned.  
The sample recruited only 22 per cent of those eligible to take part in the study. However, the offer 
to take part in this research and to receive this treatment came through cold calling by the clinical 
team through letter, e-mail or telephone call. If participants were prepared for the possibility of 
receiving CES by the IAPT services then uptake of CES might be higher.  A strength of cold calling and 
lack of research team contact is that placebo responses to CES may have been low because of 
infrequent contact of the research team so that the effectiveness of CES in the study was not 
inflated compared to clinical practice.  
Another limitation of the study was that the sample lacked ethnic diversity.  The sample was drawn 
from all ages although there were greater proportions of younger and middle aged participants in 
the study, reflecting the composition of age groups in routine IAPT NHS services. As expected the 
vast majority of patients with GAD were female. There was a broad representation of education, 
marital status and employment status reflecting the age composition of the sample.  
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There was a high degree of attrition of the study to follow up with the loss of 55.2% by 24 weeks 
despite financial incentive to provide data as opposed to 40% that we had anticipated. The study 
was adequately powered because CES was more effective than we had expected. The results are 
similar between the ITT sample with imputed results and those completing all follow up assessments 
suggesting that the conclusions drawn from the whole sample using imputation are probably safe to 
make. We also only have a limited amount of information on the reasons that participants withdrew 
from CES or follow up. The most common reason given for withdrawal from CES is not being able to 
find the time to use CES for 60 minutes per day. The CES device was also not locked so some 
participants may have used a higher current than we instructed them to and got adverse effects that 
they chose not to report. We have no evidence that anyone did this. Almost as many dropped out of 
CES because it had worked as those who stopped because it did not. A limitation of the health 
economics analysis is that we did not consider the possibility that CES  might have reduced the delay 
in receiving iCBT by freeing up capacity in other CBT therapists or that those patients who received 
both CES and iCBT might have had fewer iCBT sessions. Therefore cost savings from CES may be 
underestimated in treatment settings offering iCBT for GAD.  
We did not personalise CES to each individual. It is possible that different waveforms of current, 
stimulus intensity and stimulation location might have been more efficacious for some participants 
(Guleyupoglu et al, 2013). Some participants may have tolerated 5 days of treatment with CES per 
week better than 7 days per week with higher completion rates of 6-12 weeks CES treatment. 
As well as improvements in anxiety, there were improvements in depression and insomnia, two 
other potential indications for CES. Although the results are encouraging, further research is needed 
in patients with primary depression and primary insomnia disorders. There were also high remission, 
recovery and reliable improvement rates in GAD-7 score when participants received both iCBT and 
CES in the first 12 weeks. Research might explore if higher and more sustained rates of remission are 
in generalised anxiety disorder in trials of iCBT plus active CES versus iCBT plus sham CES. 
In conclusion, we provide evidence that CES may be clinically effective and cost reducing during 
administration and for three months afterwards in routine treatment settings offering psychological 
treatments for moderate to severe GAD. CES improves the efficiency of these services, a critical issue 
because of the shortage and high turnover of psychological treatment staff, allowing them to reach 
their targets for remission with fewer highly skilled staff. As a result, it is also cost saving to such 
services even when a range of different assumptions are made about the delivery of psychological 
treatment.  
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Table 1. Procedure and assessments in the study (n=161) 
ASSESSMENT VISIT 1 
BASELINE 
VISIT 2 
WEEK 4 
VISIT 3 
WEEK 6 
VISIT 4 
WEEK 8 
VISIT 5 
WEEK 12 
VISIT 6 
WEEK 24 
CONSENT X      
TRAINING TO 
USE CES 
X      
PREGNANCY 
TEST 
X (*)      
GAD-7 X X X X X X 
EQ-5D-5L X X X X X X 
CSRI X    X X 
WASA X X X X X X 
PHQ-9 X X X X X X 
AIS X X X X X X 
ALPHA-STIM 
CES  
Ongoing Ongoing Ongoing 
(**) 
Ongoing 
(**) 
Ongoing 
(**) 
 
ADHERENCE     X X X (**) X (**)  
ADVERSE 
EVENTS 
 X X X (**) X (**)  
 
(*) If a female of child-bearing potential 
(**) If continuing with Alpha-Stim AID CES treatment between week 6 – week 12. 
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Figure 1. Decision Tree model for comparison of Alpha-stim CES pathway with individual cognitive 
behaviour therapy (iCBT) treatment as usual. 
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Figure 2: Flow into Study 
  
Assessed for eligibility (n=743): 
met study inclusion criteria on 
IAPT database 
Excluded (n=582) 
   Not meeting inclusion criteria (n= 1) 
   Declined to participate (n=581) 
 
Analysed (n=161,100%) 
 
4 weeks: (n=120, 75%). Lost to follow-up (n=41, 25%). Stopped Alpha-Stim CES (n=25, 15.5%), 
Received iCBT (n=43, 26.7%) 
Allocated to and received intervention (n=161) 
 
Allocation 
Analysis 
Follow-Up 
Entered (n=161) 
Enrolment 
6 weeks: (n=94, 58.3%). Lost to follow up (n=67, 41.7%). Stopped Alpha-Stim CES (n=39, 24.2%). 
Received iCBT (n=47, 29.2%) 
8 weeks: (n=89, 55.3%). Lost to follow up (n=72, 44.7%). Stopped Alpha-Stim CES (n=42, 26.1%). 
Received iCBT (n=56, 34.8%) 
12 weeks: (n=81, 50.3%). Lost to follow up (n=80, 49.7%). Stopped Alpha-Stim CES (n=49, 30.4%). 
Received iCBT (n=80, 49.7%) 
24 weeks: (n=72, 44.7%). Lost to follow up (n=89, 55.2%). Received iCBT (n=80, 49.7%) 
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Table 2. Baseline characteristics of participants (n=161). 
Variable Mean (sd) or n(%) 
Age, years 38.00 (14.2) (min=18, max=76) 
Gender, female 118 (73.3%) 
Ethnicity, white British 153 (95.0%) 
Marital status: Married or cohabiting 
                           Single 
                           Divorced 
                           Widowed 
 95 (59.0%) 
 50 (31.1%) 
 12 (7.5%) 
   4 (2.5%) 
Education: No qualifications 
                    GCSE ( left school at 16 years) 
   A level or other non-degree higher qualification 
                    Degree  
   5 (3.1%) 
 39 (24.2%) 
 67 (41.6%) 
 50 (31.1%) 
Employment: Employed 
                         Unemployed 
                         Retired 
                         Student 
                         Homemaker 
106 (65.8%) 
 33 (20.5%) 
 11 (6.8%) 
   7 (4.3%) 
   4 (2.5%) 
GAD-7 15.77 (3.21) 
PHQ-9 16.07 (4.94) 
Athens Insomnia Scale 12.91 (4.82) 
WASA 20.81 (7.74) 
EQ-5D-5L 51.61 (19.0) 
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Table 3:  Intention to treat analysis of remission, reliable improvement, recovery and mean (sd) 
continuous outcomes with Alpha-stim CES at 12 and 24 weeks (n=161). 
Outcome Remission 
12 weeks 
 n (%) 
Reliable 
improve 
12 weeks 
 n (%) 
Recovery 
12 weeks  
n (%) 
Remission 
24 weeks 
n (%) 
Reliable 
improve 
24 weeks 
n (%) 
Recovery 
24 weeks 
n (%) 
GAD-7 
Overall, n=161 
No CBT, n=81 
 
72 (44.7) 
49 (60.5) 
 
102 (63.4) 
  67 (82.7) 
 
72 (44.7) 
49 (60.5) 
 
77 (47.8) 
53 (65.4) 
 
105 (65.2) 
  70 (86.4) 
 
77 (47.8) 
53 (65.4) 
PHQ-9 
Overall, n=161 
 
73 (45.3) 
 
 76 (47.2) 
 
61 (37.9) 
 
82 (50.9) 
 
80 (49.7) 
 
67 (41.6) 
GAD-7 and PHQ-9 
Overall, n=161 
 
62 (38.5) 
 
75 (46.6) 
 
54 (37.5) 
 
69 (42.9) 
 
75 (46.6) 
 
59 (36.5) 
AIS 
Overall, n=161 
 
39 (24.2) 
 
53 (32.9) 
 
37 (23.0) 
 
45 (28.0) 
 
60 (37.3) 
 
43 (26.7) 
 Normal 
Function 
12 weeks 
n (%) 
Functional 
recovery 
12 weeks 
n (%) 
 Normal 
Function 
24 weeks 
n (%) 
Functional 
recovery 
24 weeks 
n (%) 
 
WASA 
Overall, n=161 
 
28 (17.4) 
 
43 (26.7) 
  
29 (18.0) 
 
48 (29.8 
 
Outcome  Baseline 4 weeks 6 weeks 8 weeks 12 weeks 24 weeks 
GAD-71 15.77 (3.21)  10.14 (4.86) 9.73 (4.89) 9.34 (4.58) 8.92 (5.42) 8.99 (6.18) 
PHQ-92 16.07 (4.94) 11.22 (6.09)  10.38 (5.91) 10.04 (6.46) 8.91 (5.78)  10.42 (6.97) 
AIS3 12.91 (4.82) 10.27 (5.27) 10.18 (5.20) 9.72 (5.16) 8.81 (4.86) 7.94 (4.62) 
WSAS4 20.81 (7.74) 18.27 (8.89)  16.95 (9.56) 15.94 (9.22) 14.89 (9.99) 15.98 (9.18) 
EQ-5D-5L5 51.61 (19.00) 57.90 (20.15) 61.00 (20.47) 62.99 (21.08) 64.80 (21.72) 62.50 (22.97) 
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1 Effect of treatment over time significant F =88.12, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.74 (large); within 
subjects effect over time significant F=72.02, df1=3.7/df2=563.74, p < .001, partial Eta square = 0.31 (medium) 
2 Effect of treatment over time significant F=28.38, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.48 (medium); within 
subjects effect over time significant F=42.89, df1=3.9/df=559.01, p < .001, partial Eta square = 0.21 (small) 
3
 Effect of treatment over time significant F=40.85, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.57 (large); within 
subjects effect over time significant F=42.69, df1=3.8/df=542.9, p < .001, partial Eta square = 0.21 (medium) 
4
 Effect of treatment over time significant F=17.18, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.36 (medium); within 
subjects effect over time significant F=17.35, df1=3.5/df=557.45, p < .001, partial Eta square = 0.10 (small) 
5
 Effect of treatment over time not significant F=16.11, df1=5.0/df2=156.0, p < .001, partial Eta square = 0.34 (medium); 
within subjects effect over time significant F=13.94, df1=4.1/df2=651.3, p < .001, partial Eta square = 0.08 (small) 
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Table 4: Costs and responses of Alpha-Stim CES in relation to the eight session standard care 
model of CBT 
 
 
 
      
 Deterministic Probabilistic Distribution Alpha Beta N int N control 
Cost of 
Individual CBT 
 
£887.68 
 
£923.64 
 Gamma 
         
£        
887.68  
 1    
Probability of 
Response to 
Individual CBT 
 54.2% 56% Beta 199.46 168.54 368 679 
Patients per 
Alpha-Stim CES 
lifetime 
 5.00 5.41 Gamma 5 1     
Per patient cost 
of Alpha-Stim 
CES £70.00 £64.75 Calculated         
Probability of 
Response to 
Alpha-Stim CES 
 47% 39% Beta 45 55     
 
Expected Lower Upper Expected Lower Upper 
 
Cost 95% CI 95% CI Responses 95% CI 95% CI 
iCBT only £1,294,233 £1,198,677 £1,392,923 701.68 650.29 751.85 
AlphaStim   £753,355 £651,653 £981,087 889.24 860.29 907.14 
Net  -£540,878    -£648,692 -£327,117 187.56 141.03 227.82 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
25 
 
 
 
 
Appendix 
Figure 1. Cost outcome scatterplot Alpha-Stim CES versus 8 session standard care model of iCBT 
(n=1,000 patients). 
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Figure 2. Costs, responses and cost outcome scatterplot of Alpha-Stim CES in relation to “Clark and 
Wells” model of iCBT ( n=1,000 patients). 
a) Costs and responses 
 
Expected Lower Upper Expected Lower Upper 
 
Cost 95% CI 95% CI 
Response
s 95% CI 95% CI 
iCBT only 
£4,065,53
2 
£3,864,92
7 
£4,276,99
4 701.68 649.80 750.47 
AlphaStim 
£2,216,60
1 
£1,910,09
7 
£2,725,43
7 889.24 859.69 907.77 
Net 
-
£1,848,931 
-
£2,157,449 
-
£1,353,948 187.56 142.93 226.91 
 
b) Cost outcome scatterplot 
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Figure 3. Costs, responses and cost outcome scatterplot of Alpha-Stim CES in relation to the 
“Heimberg” model of iCBT (n=1,000 patients). 
a) Costs and responses. 
 
Expected Lower Upper Expected Lower Upper 
 
Cost 95% CI 95% CI 
Response
s 95% CI 95% CI 
iCBT only £2,717,082 £2,563,803 
£2,875,90
3 
701.68 649.80 750.47 
AlphaStim £1,504,619 £1,294,512 
£1,876,59
1 
889.24 859.69 907.77 
Net 
-£1,212,463 -£1,417,929 -£848,589 187.56 142.93 226.91 
 
b) Cost outcome scatterplot. 
 
 
